公开(公告)号：US4240889A

公开(公告)日：1980-12-23

申请号：US6070

申请日：1979-01-24

申请人： Kentaro Yoda ,  Rintaro Urakabe ,  Toshio Tsuchida

发明人： Kentaro Yoda ,  Rintaro Urakabe ,  Toshio Tsuchida

IPC分类号： G01N27/327 ,  C12Q1/00 ,  C12Q1/26

CPC分类号： C12Q1/002 ,  Y10S435/817

摘要： An enzyme electrode comprising an anode, a cathode, an immobilized enzyme membrane, and an electrolyte, which is characterized in that said membrane consists of a dense skin layer having selective hydrogen peroxide permeability and a porous layer wherein the enzyme is immobilized onto the porous layer of the membrane and said immobilized enzyme membrane is arranged in the electrode so that the skin layer is faced to the electrode and the porous layer immobilized with the enzyme is in the position of contacting with the test solution. The enzyme electrode is used for the polarographic determination of a slight amount of components in body fluid, body tissue, foodstuffs, or the like without any undesirable hindrance with low molecular interfering materials without using any other specific means for removing such low molecular interfering materials.

摘要翻译： 一种包含阳极，阴极，固定化酶膜和电解质的酶电极，其特征在于，所述膜由具有选择性过氧化氢渗透性的致密表皮层和多孔层组成，其中酶固定在多孔层上 的膜，并且所述固定化酶膜布置在电极中，使得皮肤层面向电极，并且固定有酶的多孔层处于与测试溶液接触的位置。 酶电极用于极限测定体液，身体组织，食品等中的少量组分，而不用任何其它具体的去除这种低分子干扰物质的具体方法，而不会对低分子干扰物质产生不期望的障碍。

公开(公告)号：US4216065A

公开(公告)日：1980-08-05

申请号：US049092

申请日：1979-06-18

申请人： Garry A. Rechnitz ,  Mark A. Arnold ,  Mark E. Meyerhoff

发明人： Garry A. Rechnitz ,  Mark A. Arnold ,  Mark E. Meyerhoff

IPC分类号： C12Q1/00 ,  G01N27/30 ,  G01N33/68 ,  G01N27/46

CPC分类号： G01N33/6812 ,  C12Q1/002 ,  C12Q1/005 ,  G01N27/304

摘要： A bio-selective potentiometric electrode probe for the determination of amino acid concentrations in aqueous liquids comprising an ammonia gas analytical electrode provided at its tip with a closely adjacent thin layer of a fresh animal tissue containing, as a natural constituent thereof, an enzyme effective to catalyze degradation of the specific amino acid in analysis to either ammonia or to an intermediate compound subject to further degradation to ammonia by an additional enzyme, which ammonia is a function of the amino acid concentration in the liquid.

摘要翻译： 一种用于测定含水液体中氨基酸浓度的生物选择性电位电极探针，其包含在其尖端处提供的氨气分析电极，其邻近的新鲜动物组织的薄层含有作为其天然成分的酶， 催化分解成特定氨基酸对氨或通过另外的酶进一步降解为氨的中间体化合物的降解，氨是液体中氨基酸浓度的函数。

公开(公告)号：US4073713A

公开(公告)日：1978-02-14

申请号：US708399

申请日：1976-07-26

申请人： David P. Newman

发明人： David P. Newman

IPC分类号： C12Q1/00 ,  G01N27/30 ,  G01N27/333 ,  G01N27/40 ,  G01N27/46

CPC分类号： C12Q1/002 ,  G01N27/3271 ,  Y10S435/817 ,  Y10T428/2495

摘要： A laminated membrane for use with an enzyme electrode without the need for use of a compensating electrode. The laminated membrane comprises a layer of essentially homogeneous material such as cellulose acetate or silicone rubber which will prevent passage of even low molecular weight interfering materials, an adhesive layer containing the enzyme (with or without other materials that may be blended with it), and a layer of support film which will also prevent the passage of high molecular weight interfering materials.

摘要翻译： 用于酶电极而不需要使用补偿电极的层压膜。 层压膜包括基本均匀的材料层，例如乙酸纤维素或硅橡胶，其将防止均匀的低分子量干扰材料通过，含有酶的粘合剂层（具有或不具有可与其混合的其它材料），以及 还可以防止高分子量干扰材料通过的一层支撑膜。

公开(公告)号：US4061466A

公开(公告)日：1977-12-06

申请号：US621888

申请日：1975-10-14

申请人： Ingvar Gosta Holger Sjoholm ,  Nils Roger Lindmark ,  Bo Magnus Ekman

发明人： Ingvar Gosta Holger Sjoholm ,  Nils Roger Lindmark ,  Bo Magnus Ekman

IPC分类号： G01N33/545 ,  A61K9/16 ,  A61K39/00 ,  A61K39/385 ,  A61K39/44 ,  B01J13/14 ,  C12N11/04 ,  C12N11/08 ,  C12Q1/00 ,  G01N33/543 ,  G01N33/549 ,  G01N33/16 ,  G01N31/14

CPC分类号： C12Q1/002 ,  A61K9/1635 ,  A61K9/167 ,  B01J13/14 ,  G01N33/549 ,  Y10S436/816 ,  Y10S436/828 ,  Y10S530/813 ,  Y10S530/817

摘要： Immobilized biologically active substances comprising microporous, spherical particles in gel form and in the form of a three-dimensional network. These particles contain the biologically active substance entrapped in the meshes of the network. The particles have sizes below 10 .mu.m and the average diameter of the particles is in the range of from 0.5 to 4 .mu.m, preferably 1 .mu.m. The biologically active substance is capable of exerting its biological activity against substances which cannot penetrate into the meshes of the network of the particles. Preferably, the particles are gel grains obtained by copolymerization of acrylic compounds with cross-linkers. The immobilized biologically active substances are used for labelling or separation of cells, cell fragments, viruses or tissue structures having specific receptors or of substances having specific surface structures.

摘要翻译： 固定的生物活性物质包括凝胶形式的微孔，球形颗粒和三维网络的形式。 这些颗粒含有捕获在网络网格中的生物活性物质。 颗粒的尺寸低于10μm，颗粒的平均直径在0.5-4μm的范围内，优选1μm。 生物活性物质能够发挥其对不能渗透到颗粒网络的网格中的物质的生物活性。 优选地，颗粒是通过丙烯酸类化合物与交联剂共聚得到的凝胶颗粒。 固定的生物活性物质用于标记或分离具有特异性受体的细胞，细胞碎片，病毒或组织结构或具有特定表面结构的物质。

公开(公告)号：US3788950A

公开(公告)日：1974-01-29

申请号：US3788950D

申请日：1970-08-05

申请人： DU PONT

发明人： HICKS G ,  UPDIKE S

IPC分类号： C08F2/44 ,  C12Q1/00 ,  C12Q1/26 ,  G01N31/14

CPC分类号： C08F2/44 ,  C12Q1/00 ,  C12Q1/002 ,  C12Q1/26

摘要： A SUBSTANTIALLY RIGID ENZYME GEL, USEFUL IN PROCESS INCORPORATING ENZYME CATALYSTS, SUCH AS SUBSTRATE ANALYSIS, COMPRISING A POLYMER MATRIX HAVING WATER COLLOIDALLY DISPERSED THEREIN AND ACTIVE ENZYME MOLECULES DISTRIBUTED HOMOGENEOUSLY THROUGHOUT AND SUBSTANTIALLY UNREACTED WITH THE POLYMER MATRIX THE POLYMER MATRIX HAVING A SUFFICIENTLY SMALL PORE SIZE TO RETAIN INDIVIDUAL ENZYME MOLECULES, I.E. THE ENZYME IN AQUEOUS SOLUTION. THE GEL IS FORMED BY POLYMERIZING AN AQUEOUS SOLUTION OF A MONOMER, FOR EXAMPLE AN ACRYLAMIDE, CONTAINING AN ENZYME UNDER CONDIDTIONS NOT DETRIMENTAL TO THE ACTIVITY OF THE ENZYME.

公开(公告)号：US20240093260A1

公开(公告)日：2024-03-21

申请号：US18184130

申请日：2023-03-15

申请人： KABUSHIKI KAISHA TOSHIBA

发明人： Tatsuro SAITO

IPC分类号： C12Q1/00 ,  G01N27/414 ,  G01N33/00

CPC分类号： C12Q1/002 ,  G01N27/4145 ,  G01N33/0027

摘要： According to one embodiment, a sensing device includes a component incorporating unit, enzyme-immobilized tank, an enzyme capture tank, a substrate tank and a sensor.

公开(公告)号：US11662329B2

公开(公告)日：2023-05-30

申请号：US16430057

申请日：2019-06-03

申请人： Instrumentation Laboratory Company

发明人： Xiaoxian Xu

IPC分类号： G01N27/327 ,  C12Q1/00 ,  G01N27/333 ,  G01N33/70 ,  G01N33/96 ,  G01N27/30 ,  C12Q1/54 ,  G01N33/53 ,  G16H10/40 ,  G16B25/30 ,  G06F17/18 ,  C12Q1/58 ,  G01N33/543 ,  G06F30/331

CPC分类号： G01N27/3275 ,  C12Q1/002 ,  C12Q1/003 ,  C12Q1/005 ,  C12Q1/54 ,  G01N27/308 ,  G01N27/3272 ,  G01N27/3276 ,  G01N27/3335 ,  G01N33/5308 ,  G01N33/70 ,  G01N33/96 ,  G06F17/18 ,  G16B25/30 ,  G16H10/40 ,  C12Q1/58 ,  G01N27/3274 ,  G01N33/5438 ,  G06F30/331

摘要： Disclosed herein are compositions for permeable outer diffusion control membranes for creatinine and creatine sensors and methods of making such membranes.

公开(公告)号：US20180238824A1

公开(公告)日：2018-08-23

申请号：US15438734

申请日：2017-02-21

申请人： QUALCOMM Incorporated

发明人： Yong Ju LEE ,  Joung Won PARK

IPC分类号： G01N27/327 ,  G01N27/414 ,  C12Q1/68 ,  G01N27/407 ,  C12Q1/00 ,  G01N33/487

CPC分类号： C12Q1/002 ,  C12Q1/6869 ,  C12Q1/6874 ,  C12Q2565/607 ,  G01N27/4145 ,  G01N33/48721 ,  C12Q2563/116 ,  C12Q2565/631

摘要： The disclosure generally relates to a deoxyribonucleic acid (DNA) sequencing circuit having a controllable pore size and a lower membrane capacitance and noise floor relative to biological nanopore devices. For example, design principles used to fabricate a fin-shaped field effect transistor (FinFET) may be applied to form, on a first wafer, a nanopore that has a desired pore size in a silicon-based membrane. Electrodes and an interconnect embedded with an amplifier and analog-to-digital converter (ADC) may be formed on a separate second wafer, wherein the first wafer and the second wafer may then be bonded and further processed to form a sensing device that includes appropriate wells and pores to be used in a DNA sequencing circuit.

公开(公告)号：US20180231491A1

公开(公告)日：2018-08-16

申请号：US15332657

申请日：2016-10-24

申请人： THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY

发明人： XINYU LIU ,  XIAO LI ,  CHEN ZHAO ,  HAO FU

IPC分类号： G01N27/327 ,  C12Q1/00 ,  H01G11/36 ,  G01N33/543

CPC分类号： G01N27/3278 ,  C12Q1/002 ,  G01N33/48721 ,  G01N33/5438 ,  G01N33/54393 ,  H01G9/042 ,  H01G11/36

摘要： A biosensor device comprises a substrate base having a paper body, the substrate base supporting at least a first electrode having a growth nanomaterial surface on a portion thereof adapted to receive a sample fluid, and a contact end configured for connection to measuring equipment. A substrate cover has a paper body, the substrate cover defining a reaction zone in which the paper is exposed on both sides of the paper body, the substrate cover supporting at least a second electrode and at least a third electrode each having a connection end contacting the reaction zone and a contact end configured for connection to the measuring equipment, wherein the reaction zone is superposed on the growth nanomaterial surface during use for wicking of the sample fluid through the reaction zone.

公开(公告)号：US20170370907A1

公开(公告)日：2017-12-28

申请号：US15613052

申请日：2017-06-02

申请人： ACEA Biosciences, Inc.

发明人： Yama A. Abassi ,  Naichen Yu ,  Josephine Atienza ,  Xiao Xu ,  Xiaobo Wang

IPC分类号： G01N33/50 ,  G01N33/543 ,  C12Q1/00 ,  G01N27/02

CPC分类号： G01N33/5041 ,  C12Q1/002 ,  G01N27/021 ,  G01N33/5014 ,  G01N33/5438 ,  G01N2333/4716 ,  G01N2333/705 ,  G01N2333/91205 ,  G01N2500/04 ,  G01N2500/10

摘要： A method of identifying a potential therapeutic compound that affects a Receptor Tyrosine Kinase (RTK) pathway in cancer cells, which includes: providing a device capable of measuring cell-substrate impedance; culturing cancer cells in serum-free media in at least two wells of the device; adding to a first well a proposed therapeutic compound that affects a RTK pathway and a RTK stimulating factor for the RTK pathway to form a test well, and adding to another well the RTK stimulating factor to form a control well; continuously monitoring cell-substrate impedance of the at least two wells and optionally determining cell indices from the monitored cell-substrate impedance; and determining a difference in impedance or optionally cell index between the test well and control well; and if significantly different, concluding the proposed therapeutic compound is therapeutically active in the RTK pathway within the cancer cells.